Group structure
4 companies in 3 countries
Canada1
Headquarters not stated1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Loading your page…
Loading your page…
4 companies in 3 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine of every company in the group, current ones first.
1–25 of 55
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALBUMINA LFBSoluzione per infusione | Albumin | Italy | Authorised | |
| CEVENFACTAPolvere e solvente per soluzione iniettabile | Coagulation factor viia | Italy | Authorised | |
| Cevenfacta | Coagulation factor viia | EU (EMA) | Authorised | 2022 |
| CEVENFACTA 1 MG (45 KIU) POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE1 mg · Polvo y disolvente para solución inyectable | Eptacog beta activado | Spain | Marketed | 2023 |
| CEVENFACTA, 1mg, poeder en oplosmiddel voor oplossing voor injectiePoeder en oplosmiddel voor oplossing voor injectie | Coagulation factor viia | Netherlands | Authorised | 2022 |
| CEVENFACTA 2 MG (90 KIU) POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE2 mg · Polvo y disolvente para solución inyectable | Eptacog beta activado | Spain | Marketed | 2023 |
| CEVENFACTA, 2mg, poeder en oplosmiddel voor oplossing voor injectiePoeder en oplosmiddel voor oplossing voor injectie | Coagulation factor viia | Netherlands | Authorised | 2022 |
| CEVENFACTA 5 MG (225 KIU) POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE5 mg · Polvo y disolvente para solución inyectable | Eptacog beta activado | Spain | Marketed | 2023 |
| CEVENFACTA, 5mg, poeder en oplosmiddel voor oplossing voor injectiePoeder en oplosmiddel voor oplossing voor injectie | Coagulation factor viia | Netherlands | Authorised | 2022 |
| Fibclot 1,5 g, poeder en oplosmiddel voor oplossing voor injectie/infusiePoeder en oplosmiddel voor oplossing voor injectie, Poeder en oplosmiddel voor oplossing voor infusie | Human fibrinogen | Netherlands | Authorised | 2016 |
| FIBCLOT 1,5 G POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE Y PARA PERFUSION1,50 g · Polvo y disolvente para solución inyectable y para perfusión | Human fibrinogen | Spain | Marketed | 2017 |
| FIBRICLOTTEPolvere e solvente per soluzione iniettabile/ per infusione | Human fibrinogen | Italy | Authorised | |
| IQYMUNESoluzione per infusione | Immunoglobulina umana normale | Italy | Authorised | |
| IQYMUNE 100 mg/ml, oplossing voor infusieOplossing voor infusie | Humaan, normaal immunoglobuline voor intraveneus gebruik | Netherlands | Authorised | 2016 |
| IQYMUNE 100 MG/ML SOLUCION PARA PERFUSION100 mg · Solución para perfusión | Inmunoglobulina humana | Spain | Marketed | 2016 |
| Sevenfact5MG · Injection | Coagulation factor viia | United States | Marketed | 2020 |
| Sevenfact2MG · Injection | Coagulation factor viia | United States | Not marketed | 2024 |
| Sevenfact1MG · Injection | Coagulation factor viia | United States | Marketed | 2020 |
| WILFACTINPolvere per sospensione iniettabile | Fattore von willebrand | Italy | Authorised | |
| Wilfactin 100 IE/ml, poeder en oplosmiddel voor oplossing voor injectiePoeder en oplosmiddel voor oplossing voor injectie | Von willebrand factor | Netherlands | Authorised | 2008 |
| ANTIDOULEURS REZALL180 mg / 30 ml + 600 mg / 30 ml · Liquid | Antipyrine, Sodium salicylate | Canada | Cancelled | 1930 |
| ATryn | Antithrombin iii | EU (EMA) | Withdrawn | 2006 |
| BRONCHO TUSS ADULT100 mg / sup + 7.5 mg / sup + 60 mg / sup · Suppository | Guaifenesin, Ephedrine, Camsylate | Canada | Cancelled | 1981 |
| BRONCHO TUSS INFANT25 mg / sup + 2.5 mg / sup + 25 mg / sup · Suppository | Guaifenesin, Ephedrine, Camsylate | Canada | Cancelled | 1981 |
| COLLYRE HYGIENIQUE SOKER11.1 mg / ml + 1.89 mg / ml · Liquid | Boric acid | Canada | Cancelled | 1978 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 34 | 0 | 34 | CompaniesAll medicines |
| Netherlands | 6 | 6 | 0 | CompaniesAll medicines |
| Spain | 5 | 5 | 0 | CompaniesAll medicines |
| Italy | 5 | 5 | 0 | CompaniesAll medicines |
| United States | 3 | 3 | 0 | CompaniesAll medicines |
| European Union (EMA) | 2 | 1 | 1 | CompaniesAll medicines |
Also in the registers of United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Report an error or request removalCorrections from the company itself are welcome.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Well-known pharmaceutical groups, each with all its companies.